Names | |
---|---|
IUPAC name
rel-(6R,10bS)-6-[4-(Methylsulfanyl)phenyl]-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline | |
Other names
trans-McN-5652 | |
Identifiers | |
| |
3D model (JSmol) |
|
ChEMBL | |
ChemSpider |
|
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C19H21NS | |
Molar mass | 295.44 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
McN5652[1] is a molecule that can be radiolabeled and then used as a radioligandinpositron emission tomography (PET) studies. The [11C]-(+)-McN5652 enantiomer binds to the serotonin transporter.[2] The radioligand is used for molecular neuroimaging and for imaging of the lungs.[3]
It was developed by Johnson & Johnson's McNeil Laboratories. According to McNeil, McN5652 was among the strongest SRI ever reported at the time of its discovery (sub nM Ki). However, it is not completely 5-HT selective: the racemate has 5-HT=0.68, NA=2.9, and D=36.8nM, whereas (+)-enantiomer has 5-HT=0.39, NA=1.8, and D=23.5 nM. Paroxetine was listed as 5-HT=0.44 nM, NA=20, and DA=460nM in the same paper by the same authors.
McN5652 and related structures have been analyzed for QSAR in terms of binding to the MAT receptor binding site.[4]
This neuroscience article is a stub. You can help Wikipedia by expanding it. |